Venlafaxine but not bupropion decreases cerebrospinal fluid 5- hydroxyindoleacetic acid in unipolar depression

Biological Psychiatry

Volumn 45, Issue 3, 1999, Pages 285-289

  Little, John T ^a   Ketter, Terence A ^b   Mathé, Aleksander A ^c   Frye, Mark A ^a   Luckenbaugh, Dave ^a   Post, Robert M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

5 hydroxyindoleacetic acid; Bupropion; Cerebrospinal fluid; Depression; Serotonin; Venlafaxine

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; AMFEBUTAMONE; DOPAMINE RECEPTOR STIMULATING AGENT; HOMOVANILLIC ACID; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ARTICLE; BRAIN METABOLISM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; MONOAMINERGIC SYSTEM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; BUPROPION; CROSS-OVER STUDIES; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE; SEROTONIN;

EID: 0033083294     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00078-X     Document Type: Article

References (30)

1. Åberg-Wistedt A., Alvariza M., Bertilsson L., Malmgren R., Wachtmeister H. Alaproclate a novel antidepressant? Acta Psychiatr Scand. 71:1985;256-268.
2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC.
3. Åsberg M., Ringberger V.-A., Sjöqvist F., Thorén P., Träskman L., Tuck J.R. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin Pharmacol Ther. 21:1977;201-207.
4. Ascher J.A., Cole J.O., Colin J.-N., et al. Bupropion A review of its mechanism of antidepressant activity . J Clin Psychiatry. 56:1995;395-401.
5. Bertilsson L., Tuck J.R., Siwers B. Biochemical effects of zimelidine in man. Eur J Clin Pharmacol. 18:1980;483-487.
6. Bianchine J., McConnell H. CSF as a reflection of cerebral metabolism. McConnell H., Bianchine J. Cerebrospinal Fluid in Neurology and Psychiatry. 1994;35-42 Chapman & Hall Medical, London.
7. Bowden C.L., Koslow S.H., Hanin I., Maas J.W., Davis J.M., Robins E. Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. Clin Pharmacol Ther. 37:1985;316-324.
8. De Bellis M.D., Geracioti T.D., Altemus M., Kling M.A. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol Psychiatry. 33:1993;636-641.
9. Endicott J., Spitzer R.L. A diagnostic interview The schedule for affective disorders and schizophrenia . Arch Gen Psychiatry. 35:1978;837-844.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). 1995;New York State Psychiatric Institute, Biometrics Research Department, New York.
11. Golden R.N., Rudorfer M.V., Sherer M.A., Linnoila M., Potter W.Z. Bupropion in depression. Arch Gen Psychiatry. 45:1988;139-143.
12. Guy E, editor (1976): ECDEU Assessment Manual for Psychopharmacology, (Reprinted 1991, DHEW Pub. No. (ADM)76-338). Rockville, MD: National Institute of Mental Health.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
14. Lundmark J., Wålinder J., Alling C., Manniche P.M., Dalgaard L. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients. Eur Neuropsychopharmacol. 4:1994;1-6.
15. Major L.F., Murphy D.L., Lipper S., Gordon E. Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem. 32:1979;229-231.
16. Mårtensson B., Nyberg S., Toresson G., Brodin E., Bertilsson L. Clinical effects, drug concentrations and monamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand. 79:1989;586-596.
17. 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr Scand. 83:1991;125-133.
18. McConnell H. CSF in psychiatric illness. McConnell H., Bianchine J. Cerebrospinal Fluid in Neurology and Psychiatry. 1994;173-216 Chapman & Hall Medical, London.
19. Special feature Rating scales and assessment instruments for use in pediatric psychopharmacology research . Psychopharmacol Bull. 21:1985;839-843.
20. Nordin C., Siwers B., Bertilsson L. Bromocriptine treatment of depressive disorders Clinical and biochemical effects . Acta Psychiatr Scand. 64:1981;25-33.
21. Nordin C., Bertilsson L., Siwers B. Clinical and biochemical effects during treatment of depression with nortriptyline The role of 10-hydroxynortriptyline . Clin Pharmacol Ther. 42:1987;10-19.
22. Potter W.Z., Scheinin M., Golden R.N., et al. Selective antidepressants and cerebrospinal fluid. Arch Gen Psychiatry. 42:1985;1171-1177.
23. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol. 16:(suppl 2):1996;1S-9S.
24. Risby E.D., Hsiao J.K., Sunderland T., Ågren H., Rudorfer M.V., Potter W.Z. The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio. Clin Pharmacol Ther. 42:1987;547-554.
25. Sheline Y.I., Bardgett M.E., Csernansky J.G. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 17:1997;11-14.
26. Spearing M.K., Post R.M., Leverich G.S., Brandt D., Nolen W. Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP) The CGI-BP . Psychiatry Research. 73:1997;159-171.
27. Sunderland T., Cohen R.M., Molchan S., et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 51:1994;607-615.
28. Thase M.E. Antidepressant options Venlafaxine in perspective . J Clin Psychopharmacol. 16:(suppl 2):1996;10S-20S.
29. Tohgi H., Abe T., Nakanishi M., et al. Effects of citalopram, a synthetic serotonin uptake inhibitor, on indoleamine and catecholamine concentrations in the cerebrospinal fluid of freely moving rats. J Neural Transm Gen Sect. 9:1995;111-119.
30. Williams J.B.W., Link M.J., Rosenthal N.E., Terman H. Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders Version (SIGH-SAD). 1988;New York State Psychiatric Institute, New York.